Mostrando 5 resultados de: 5
Filtros aplicados
Subtipo de publicación
Article(5)
Publisher
CJC Open(1)
European Heart Journal - Cardiovascular Pharmacotherapy(1)
European Heart Journal - Quality of Care and Clinical Outcomes(1)
Journal of Stroke(1)
The Lancet Respiratory Medicine(1)
Área temáticas
Enfermedades(3)
Farmacología y terapéutica(3)
Medicina y salud(3)
Problemas sociales y servicios a grupos(2)
Cirugía y especialidades médicas afines(1)
Área de conocimiento
Medicina interna(3)
Ensayo clínico(2)
Enfermedad cardiovascular(1)
Epidemiología(1)
Farmacología(1)
Año de Publicación
2022(5)
Origen
google(4)
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
ArticleAbstract: Background: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmePalabras claves:Autores:Ali Z., Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Berwanger O., Bosch J.J., Choudhri S., Dans A.L., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Heenan L., Jolly S.S., Kontsevaya A., Loeb M., Lopes R.D., Pais P., Palileo-Villanueva L.M., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopusAssociation of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)
ArticleAbstract: Background and Purpose The association of dyslipidemia with stroke has been inconsistent, which mayPalabras claves:Apolipoproteins, Case-control, dyslipidemia, Lipoproteins, risk factor, strokeAutores:Avezum A.J., Chin S.L., Czlonkowska A., Damasceno A., Dans A.L., DIaz R., Diener H.C., ElSayed A., Ferguson J., Hankey G.J., Hussain F.A., Iqbal R., Iversen H.K., Judge C., Lanas F., Langhorne P., Lisheng L., Málaga G., McQueen M.J., Mondo C.K., Nilanont Y., Ogah O.S., Ogunniyi A., Oguz A., Oveisgharan S., O’donnell M.J., Pais P., Paré G., PATRICIO LOPEZ -JARAMILLO, Peñaherrera E., Pogosova N., Rangarajan S., Rao-Melacini P., Rosengren A., Rumboldt Z., Ryglewicz D., Sniderman A., Wang X., Weimar C., Xavier D., Yusoff K., Yusuf S., Yusufali A.M., Zhang H.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusThe Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
ArticleAbstract: Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trialsPalabras claves:Autores:Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Beresh H., Berwanger O., Bosch J.J., Chan N., Choudhri S., Dans A.L., DIaz R., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Jolly S.S., Kazmi K., Kontsevaya A., Lewis G., Loeb M., Lopes R.D., Nkeshimana M., Orlandini A., Pais P., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopusThe cost implications of a polypill for primary prevention in the TIPS-3 trial
ArticleAbstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesPalabras claves:Cardiovascular disease, cost analysis, Polypill, Primary PreventionAutores:Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.Fuentes:googlescopus